Browse the corpus
Walk the Even Hospital Database by book and chapter — the raw source passages that ground Ask, DDx, and the rest.
1 passage
CS reports grants from BMS, Ono-Pharmaceuticals, BoehringerIngelheim, Roche-Ventana, Pfizer, and Archer Dx, unrelated to this Correspondence; personal fees from Genentech, Sarah Canon Research Institute, Medicxi, Bicycle Therapeutics, GRAIL, Amgen, AstraZeneca, BMS, Illumina, GlaxoSmithKline, MSD, and Roche-Ventana, unrelated to this Correspondence; and stock options from Apogen Biotech, Epic Biosciences, GRAIL, and Achilles Therapeutics, unrelated to this Correspondence. PBM reports personal fees and non-financial support from Vifor, Napp, Pharmacosmos, Astra Zeneca, Astellas, and Novartis; and grants from Boehringer Ingelheim. RB and DLVB are members of the Genotype-to-Phenotype UK National Virology Consortium. All other authors declare no competing interests. Funding details and acknowledgments can be found in the appendix. All data (anonymised) and full R code to produce figures and statistical analysis presented in this Correspondence are available online. Members of the Haemodialysis COVID-19 consortium and the Crick COVID Immunity Pipeline are listed in the appendix.